Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell linesGisele Nishiguchi, Zoran Ranković, Kevin McGowan et al.|Nature Communications|2024Cited by 50
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020Jeffrey J. Kooijman, Guido J.R. Zaman, Wilhelmina E. van Riel et al.|Frontiers in Oncology|2022Cited by 22
Rationally Designed Potent and Selective CK1α Degraders Exert Antiproliferative Activity Against a Broad Range of Human Cancer Cell LinesZoran Ranković, Anthony A. High, Gisele Nishiguchi et al.|Research Square|2023Cited by 0
Selective CK1a Degraders Exert Antiproliferative Activity Against a Broad Range of Human Cancer Cell LinesGisele Nishiguchi, Zoran Ranković, Lauren G. Mascibroda et al.|Figshare|2024Cited by 0